San Nuo Bio: The appeal against the overseas related patent infringement was rejected, maintaining the previous preliminary injunction ruling.

LightningPacketLoss · 2026-04-04T17:33:19+00:00

Sino Biotech announced that the European Unified Patent Court dismissed its appeal against A Menarini Diagnostics, upholding the temporary ban on GlucoMen iCan CGM. This ruling is a precautionary measure and does not constitute a final judgment. The involved amount is between €200,000 and €400,000. The company will actively respond to the case, and the ultimate impact remains uncertain.

LightningPacketLoss

2026-04-04 17:33:19

Abstract generation in progress

On April 1, Sanon Biotech released an announcement stating that the Court of Appeal of the Unified Patent Court for Europe (UPC) dismissed the company’s appeal and the appeal request of A Menarini Diagnostics S.r.l., and upheld the preliminary injunction judgment issued by the Hague UPC Division against the GlucoMen iCan CGM product.

The announcement mentioned that the Unified Patent Court decision addressed in this announcement is the result of the review of an appeal against the “Preliminary Injunction (PI),” and is not a final decision on the issues in the case. The preliminary injunction is a precautionary measure taken before the final hearing of the case and does not mean that the court has made a final finding regarding infringement facts or the validity of the patents. The estimated amount involved in this ruling is between 200,000 and 400k euros.

The company is actively preparing for the main trial proceedings and responses to the case. Since the main trial has not yet opened, the final outcome remains uncertain, and the specific impact on the company’s post-event profits is also uncertain.

(Sanon Biotech announcement)

(Editor: Yang Yan, Lin Chen)

Key words:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.